Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection

Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC‡ 04-2017)

(2020) Alain Vergnenegre et al.   Future Oncology

Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review

(2020) Viktor Wichmann et al.   ACTA ONCOLOGICA

Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis

(2020) Ryan N. Hansen et al.   BMC CANCER

The Promise of Combining Radiation Therapy With Immunotherapy

(2020) Justin C. Jagodinsky et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Effects of Radiation on the Tumor Microenvironment

(2020) Arta M. Monjazeb et al.   SEMINARS IN RADIATION ONCOLOGY

ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib

(2020) Atocha Romero et al.   Translational Lung Cancer Research

LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

(2020) C. Faivre-Finn et al.   ANNALS OF ONCOLOGY

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study)

(2019) Hiroaki Akamatsu et al.   LUNG CANCER

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial

(2019) Miguel-Angel Molina-Vila et al.   Journal of Thoracic Oncology

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: a randomized phase II (RENO study)

(2018) Dolores Isla et al.   LUNG CANCER

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment

(2017) Mariano Provencio et al.   Oncotarget

Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung Cancer

(2017) Conor E. Steuer et al.   JAMA Oncology

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive forEGFRactivating mutations

(2016) E. Iwama et al.   ANNALS OF ONCOLOGY

Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development

(2016) Marina E Cazzaniga et al.   Future Oncology

On and off Metronomic Oral Vinorelbine in Elderly Women with Advanced Breast Cancer

(2015) Francesca De Iuliis et al.   TUMORI

On and off Metronomic Oral Vinorelbine in Elderly Women with Advanced Breast Cancer

(2015) Francesca De Iuliis et al.   TUMORI JOURNAL

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

(2014) Delphine Lerouge et al.   BMC CANCER

Fractionated Scheme of Oral Vinorelbine as Single-Agent Therapy or in Combination With Cisplatin Concomitantly With Thoracic Radiotherapy in Stage III Non–Small-Cell Lung Cancer: Dose-Escalation Phase I Trial

(2014) Maciej Krzakowski et al.   Clinical Lung Cancer

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group

(2013) Emmanouil Kontopodis et al.   JOURNAL OF CHEMOTHERAPY

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer

(2011) Zacharenia Saridaki et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

(2011) W. J. Curran et al.   JNCI-Journal of the National Cancer Institute

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

(2008) Nasser Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC

(2008) Lars Henrik Jensen et al.   LUNG CANCER